Arnab Basu, MD

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.

Dr Shawnta Anakwah presents the patient profile of a 72-year-old man with advanced renal cell carcinoma presenting with hematuria.

Key opinion leaders discuss the common adverse events seen with IO/IO combination regimens and how to treat patients with brain metastases.

A review of the first-line IO/IO combination regimens available for advanced RCC.

Shawnta Anakwah, MD, presents the patient profile of a 48-year-old man with advanced renal cell carcinoma presenting with a right renal mass.

Drs Anakwah and Basu share their thoughts on the duration of treatment with I/O–TKI regimens and what treatment options are available for patients at progression of renal cell carcinoma.

Experts review adverse events commonly observed with IO/TKI combination regimens in patients with RCC and how these are managed in clinical practice.

Oncologists discuss which patients with advanced RCC might be most suitable for treatment with lenvatinib + pembrolizumab and the appropriate dosing strategies for this regimen.

A review of the first-line IO/TKI combination regimens available for advanced RCC and the factors considered in choosing an appropriate treatment.

Arnab Basu, MD, presents the patient profile of a 58-year-old woman with advanced renal cell carcinoma presenting with gross hematuria.